Jan Beyer-Westendorf Selected Research

N(4)-oleylcytosine arabinoside

1/2022	First Trimester Anticoagulant Exposure and Adverse Pregnancy Outcomes in Women with Preconception Venous Thromboembolism: A Nationwide Cohort Study.
1/2022	Effectiveness and safety of edoxaban therapy in daily-care patients with atrial fibrillation. Results from the DRESDEN NOAC REGISTRY.
7/2021	The Importance of Appropriate Dosing of Nonvitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation.
4/2021	Venous Thromboembolism Therapy with Apixaban in Daily Care Patients: Results from the Dresden NOAC Registry.
1/2021	5-year outcomes from rivaroxaban therapy in atrial fibrillation: Results from the Dresden NOAC Registry.
1/2020	Rates, management and outcome of bleeding complications during edoxaban therapy in daily care - results from the DRESDEN NOAC REGISTRY.
1/2019	Non-vitamin K Antagonist Oral Anticoagulants (NOAC) as an Alternative Treatment Option in Tumor-Related Venous Thromboembolism.
1/2018	Venous thromboembolism therapy with rivaroxaban in daily-care patients: Results from the Dresden NOAC registry.
1/2018	What have we learned from real-world NOAC studies in venous thromboembolism treatment?
12/2017	Management and outcome of gastrointestinal bleeding in patients taking oral anticoagulants or antiplatelet drugs.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jan Beyer-Westendorf Research Topics

Disease

79	Hemorrhage 05/2022 - 01/2012
62	Venous Thromboembolism 01/2022 - 01/2012
23	Atrial Fibrillation 05/2022 - 08/2014
23	Neoplasms (Cancer) 05/2022 - 04/2010
20	Thrombosis (Thrombus) 12/2021 - 10/2013
18	Stroke (Strokes) 01/2022 - 04/2014
14	Venous Thrombosis (Deep-Vein Thrombosis) 12/2021 - 10/2011
14	Pulmonary Embolism 12/2021 - 01/2012
7	Thrombocytopenia (Thrombopenia) 08/2021 - 02/2014
6	Embolism (Embolus) 01/2022 - 01/2016
4	Ischemic Stroke 11/2022 - 02/2016
4	Intracranial Hemorrhages (Intracranial Hemorrhage) 05/2022 - 01/2019
4	Wounds and Injuries (Trauma) 05/2022 - 02/2015
4	Menorrhagia 05/2021 - 01/2016
3	Cerebral Hemorrhage 05/2022 - 01/2020
3	Body Weight (Weight, Body) 01/2019 - 09/2016
3	Uterine Hemorrhage (Uterine Bleeding) 10/2016 - 01/2016
2	Idiopathic Thrombocytopenic Purpura (Thrombocytopenic Purpura, Autoimmune) 08/2021 - 07/2021
2	COVID-19 07/2021 - 01/2021
2	Diabetes Mellitus 01/2021 - 08/2016
2	Heart Failure 01/2021 - 04/2015
2	Fetal Diseases (Embryopathy) 12/2020 - 09/2016
2	Vomiting 01/2019 - 01/2018
2	Critical Illness (Critically Ill) 01/2019 - 11/2018
2	Frailty 10/2018 - 01/2018
2	Fibrosis (Cirrhosis) 01/2018 - 02/2014
1	Birth Weight (Birth Weights) 01/2022
1	Hematoma 01/2022
1	Premature Birth (Birth, Premature) 01/2022
1	Thrombotic Microangiopathies 08/2021
1	Infections 07/2021
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2021
1	Dyspnea (Shortness of Breath) 01/2021
1	Hypertension (High Blood Pressure) 01/2021
1	Dyslipidemias (Dyslipidemia) 01/2021
1	Transient Ischemic Attack 01/2021
1	Obesity 01/2021
1	Congenital Abnormalities (Deformity) 12/2020
1	Shock 11/2020
1	Myocardial Infarction 10/2020
1	Peripheral Arterial Disease 10/2020
1	Ischemia 10/2020
1	Chronic Renal Insufficiency 04/2019
1	Type 2 Diabetes Mellitus (MODY) 01/2019

Drug/Important Bio-Agent (IBA)

66	AnticoagulantsIBA 05/2022 - 01/2013
56	RivaroxabanIBA 01/2022 - 01/2013
28	Vitamin K FDA Link 05/2022 - 11/2013
19	N(4)-oleylcytosine arabinosideIBA 01/2022 - 01/2012
14	Warfarin (Coumadin)FDA LinkGeneric 07/2021 - 10/2014
13	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 01/2022 - 12/2012
12	Factor Xa InhibitorsIBA 01/2022 - 11/2015
9	edoxabanIBA 05/2022 - 11/2015
9	Enoxaparin (Lovenox)FDA LinkGeneric 01/2019 - 01/2014
8	apixabanIBA 01/2022 - 01/2012
8	Pharmaceutical PreparationsIBA 07/2021 - 01/2012
7	spermatogenesis associated factor (SPAF)IBA 01/2022 - 04/2015
7	Heparin (Liquaemin)FDA LinkGeneric 01/2020 - 01/2014
7	Fondaparinux (Arixtra)FDA Link 10/2019 - 10/2011
5	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 02/2021 - 08/2015
4	PRT064445IBA 01/2022 - 01/2016
4	Platelet Aggregation Inhibitors (Antiplatelet Drugs)IBA 01/2020 - 08/2016
4	Dabigatran FDA Link 01/2018 - 10/2011
3	Prothrombin (Factor II)IBA 01/2022 - 08/2014
3	prothrombin complex concentrates (PPSB)IBA 01/2022 - 01/2020
3	Factor Xa (Coagulation Factor Xa)IBA 01/2022 - 01/2016
3	fibrin fragment D (D-dimer)IBA 12/2016 - 04/2014
2	Tissue Plasminogen Activator (Alteplase)FDA Link 11/2022 - 01/2014
2	Dalteparin (Dalteparin Sodium)FDA Link 05/2022 - 08/2018
2	VaccinesIBA 08/2021 - 07/2021
2	A-factor (Streptomyces)IBA 01/2019 - 01/2016
2	Tenecteplase FDA Link 03/2017 - 04/2014
2	tetraethylpyrazine (TEP)IBA 01/2017 - 12/2012
2	Hormones (Hormone)IBA 10/2016 - 03/2016
1	AntidotesIBA 01/2022
1	COVID-19 VaccinesIBA 08/2021
1	Inosine Triphosphate (ITP)IBA 07/2021
1	Messenger RNA (mRNA)IBA 07/2021
1	CreatinineIBA 01/2021
1	N,N-dimethylarginine (asymmetric dimethylarginine)IBA 01/2021
1	HomoarginineIBA 01/2021
1	Arginine (L-Arginine)FDA Link 01/2021
1	cyclo(Arg-Pro) (CI 4)IBA 12/2020
1	Hemoglobins (Hemoglobin)IBA 11/2020
1	TabletsIBA 01/2020
1	SuspensionsIBA 01/2020
1	omega-Chloroacetophenone (Mace)IBA 01/2019

Therapy/Procedure

48	Therapeutics 05/2022 - 04/2010
4	Catheters 12/2021 - 01/2014
3	Secondary Prevention 01/2019 - 01/2018
2	Bariatric Surgery 01/2021 - 11/2013
2	Aftercare (After-Treatment) 01/2021 - 01/2021
2	Anticoagulation Reversal 01/2021 - 01/2019
2	Surgical Amputation (Amputations) 10/2020 - 11/2017
2	Length of Stay 12/2017 - 01/2013
2	Orthopedic Procedures 01/2017 - 01/2012
2	Blood Transfusion (Blood Transfusions) 08/2016 - 02/2015
2	Thrombolytic Therapy 02/2016 - 04/2014
1	Palliative Care (Palliative Therapy) 05/2022
1	Drug Tapering 07/2021
1	Oral Administration 02/2021